FundingWatcher
Home / Startups / By venture fund / Novartis Venture Fund portfolio companies

Novartis Venture Fund portfolio companies

Updated 16 Nov 2026

http://www.nvfund.com

Novartis Venture Fund portfolio companies
One-time CSV
  • 20 funded companies, 17 with a website
  • Last round, amount, date, total raised and investors
  • CRM-ready CSV, 18 columns
  • Download right after payment
With founder contacts
Compiled to order
  • The full startup CSV, plus founders and executives
  • Up to 2 founders or CEOs per company, compiled to order
  • Name, job title and LinkedIn URL where found
  • Verified direct email per person
  • Startup CSV at once, contacts CSV by mail within 24 hours
Download right after paymentFree 10-row sampleSecure checkout by Stripe

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

startups-investor-novartis-venture-fund.csv20 rows × 18 columns
CompanyCityLast roundAmountDate
FoRx TherapeuticsBaselSeries A$50.0M2025-12-18
FundaMental PharmaHeidelbergSeed$2.9M2024-04-11
CatalYmPlaneggSeries D$150.0M2024-07-16
Lemonaid HealthSan FranciscoSeries B$36.8M2020-07-31
Binx HealthBostonSeries F$65.0M2024-04-02
Twentyeight-Seven TherapeuticsCambridgeSeries A$15.0M2019-05-09
RhygazeBaselSeries A$86.0M2025-01-10
AravaxMelbourneSeries B$22.2M2024-01-23

8 rows of the CSV in 5 of its 18 columns.

20
Startups
$1.5B
Total raised
2
Funded in the last 12 months
$50.0M
Raised in the last 12 months

Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.

Newest rounds

10 of 20
10 rows
Company What they do Sector Location Last round Amount Date Total raised Investors Employees Founded
FoRx Therapeutics FoRx Therapeutics is a biotechnology company developing cancer drugs that target DNA replication stress pathways. Biotech Basel, Switzerland Series A $50.0M 2025-12-18 $109.4M EQT Life Sciences, Novartis Venture Fund, Omega Funds +2 11 to 50 2019
Rhygaze Rhygaze develops a gene therapy that targets cone cells to restore vision in blinding diseases. Biotech Basel, Switzerland Series A $86.0M 2025-01-10 $97.3M Google Ventures, F-Prime, ARCH Venture Partners +2 11 to 50 2024
CatalYm CatalYm develops immunotherapies to treat cancer. Biotech Planegg, Germany Series D $150.0M 2024-07-16 $260.9M Bayern Kapital, Forbion Capital Partners, Novartis Venture Fund +1 11 to 50 2016
FundaMental Pharma FundaMental Pharma is a neuroscience company with preclinical-stage drug candidates. Biotech Heidelberg, Germany Seed $2.9M 2024-04-11 $13.3M HTGF (High-Tech Gruenderfonds), Novartis Venture Fund, coparion +2 1 to 10 2016
Aravax Aravax is an early stage biotechnology company developing a treatment for peanut allergy. Biotech Melbourne, Australia Series B $22.2M 2024-01-23 Novartis Venture Fund, Breakthrough Victoria, Uniseed +2 11 to 50 2015
Hyku Hyku develops covalent drugs that precisely target disease-causing proteins. Biotech Lexington, United States Seed $56.0M 2023-09-19 $56.0M KB Investment, RA Capital Management, Novartis Venture Fund +2 11 to 50 2021
Covagen Covagen develops protein-based therapeutics for inflammatory diseases and cancer. Biotech Schlieren, Switzerland Series B $66.1M 2013-12-09 Ventech, Novartis Venture Fund, Andera Partners +2 11 to 50 2007
Okairos Okairos develops genetic T-cell vaccines, including candidates targeting hepatitis C virus. Biotech Basel, Switzerland Series B $20.5M 2010-09-14 $30.1M EQT Life Sciences, Versant Ventures, Novartis Venture Fund +2 1 to 10 2007
ESBATech ESBATech develops fully human antibody fragments for therapeutic applications using the single-chain antibody framework. Biotech Schlieren, Switzerland Series B $22.0M 2008-08-07 Novartis Venture Fund, VI Partners, SV Health Investors +2 51 to 100 1998
Roche Glycart Roche Glycart researches, develops, and commercializes antibody-based biotechnology products. Biotech Schlieren, Switzerland Series A $13.6M 2003-11-26 $13.6M Forbion Capital Partners, Novartis Venture Fund, BioMedPartners +1 101 to 250 2000

Table 1. Novartis Venture Fund portfolio companies: the 10 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 20.

Largest rounds

Last 12 months
# Company What they do Sector Location Last round Amount Date Total raised Investors Employees Founded
1 FoRx Therapeutics FoRx Therapeutics is a biotechnology company developing cancer drugs that target DNA replication stress pathways. Biotech Basel, Switzerland Series A $50.0M 2025-12-18 $109.4M EQT Life Sciences, Novartis Venture Fund, Omega Funds +2 11 to 50 2019

Table 2. Novartis Venture Fund portfolio companies: the 1 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most active investors

By companies backed
#InvestorTypeLocation CompaniesShare Funded, 12 monthsLatest
1 EQT Life Sciences Private equity firm Amsterdam, The Netherlands 3 15% 1 FoRx Therapeutics
2 Forbion Capital Partners Private equity firm Naarden, The Netherlands 3 15%
3 Versant Ventures Venture capital firm Menlo Park, United States 3 15%
4 BioGeneration Ventures Micro VC fund Naarden, The Netherlands 2 10%
5 OrbiMed Private equity firm New York, United States 2 10%
6 BioMedPartners Venture capital firm Basel, Switzerland 2 10%
7 Pfizer Corporate venture arm New York, United States 1 5% 1 FoRx Therapeutics
8 Pfizer Venture Investments Corporate venture arm New York, United States 1 5% 1 FoRx Therapeutics
9 Omega Funds Secondary purchaser Boston, United States 1 5% 1 FoRx Therapeutics
10 Thuja Capital Startup accelerator Utrecht, The Netherlands 1 5%
11 HTGF (High-Tech Gruenderfonds) Venture capital firm Bonn, Germany 1 5%
12 coparion Startup accelerator Cologne, Germany 1 5%
13 Bioqube Ventures Venture capital firm Hasselt, Belgium 1 5%
14 Bayern Kapital Venture capital firm Landshut, Germany 1 5%
15 Civilization Ventures Venture capital firm San Francisco, United States 1 5%

Table 3. Novartis Venture Fund portfolio companies: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Sectors

SectorsCompaniesShareTotal raised
Health care 17 85% $1.4B
Biotech 15 75% $1.1B
Software 4 20% $245.8M
Artificial intelligence 2 10% $71.5M
Hardware 2 10% $15.7M

Table 4. Novartis Venture Fund portfolio companies by sector. Source: FundingWatcher. Data as of 16 November 2026.

Funding stage

Funding stageCompaniesShareMedian last round
Seed 2 10% $56.0M
Series A 5 25% $15.0M
Series B 7 35% $33.1M
Series C 2 10% $29.8M
Series D+ 4 20% $65.0M

Table 5. Novartis Venture Fund portfolio companies by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Countries

CountriesCompaniesShare
Switzerland 9 45%
United States 5 25%
Germany 2 10%
China 2 10%
Australia 1 5%
United Kingdom 1 5%

Table 6. Novartis Venture Fund portfolio companies by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.

Cities

CitiesCompaniesShare
Basel 3 15%
Schlieren 3 15%
Heidelberg 1 5%
Planegg 1 5%
San Francisco 1 5%
Boston 1 5%
Cambridge 1 5%
Melbourne 1 5%
Lexington 1 5%
Falmer 1 5%
Shenzhen 1 5%
Yangzhou 1 5%

Table 7. Novartis Venture Fund portfolio companies by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.

Rounds by month

Rounds by monthCompaniesShareRaised
March 2026 1 50%
December 2025 1 50% $50.0M

Table 8. Novartis Venture Fund portfolio companies: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most recent round by year

Most recent round by yearCompaniesShareRaised
2026 1 5%
2025 3 15% $136.0M
2024 5 25% $273.2M
2023 1 5% $56.0M
2020 1 5% $36.8M
2019 1 5% $15.0M

Table 9. Novartis Venture Fund portfolio companies by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Founding year

Founding yearCompaniesShare
2023 or later 1 5%
2020 to 2022 2 10%
2015 to 2019 6 30%
2010 to 2014 2 10%
Before 2010 9 45%

Table 10. Novartis Venture Fund portfolio companies by founding year. Source: FundingWatcher. Data as of 16 November 2026.

Team size

Team sizeCompaniesShare
1 to 10 3 16%
11 to 50 9 47%
51 to 100 3 16%
101 to 250 3 16%
501 to 1,000 1 5%

Table 11. Novartis Venture Fund portfolio companies by headcount. Source: FundingWatcher. Data as of 16 November 2026.

Method

Sources, fields and exclusions of both files: Method.

Questions

How many Novartis Venture Fund portfolio companies are on the list?
20, in the file dated 16 November 2026. 2 of them closed their most recent round in the last 12 months.
What does the CSV contain?
One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
How much does the list cost?
$29 one-time for all 20 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
What arrives after payment?
At once: the CSV download link, on the page after payment and by mail.
Can I see rows before buying?
The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
How current is the data?
The file is dated 16 November 2026. The download link serves the current file each time it is opened.

Novartis Venture Fund portfolio companies: 20 rows, CSV, $29 one-time.

At once: the CSV download link, on the page after payment and by mail.

Columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.

With founder contacts: $199 one-time. List CSV right after payment; up to 2 verified founder or CEO emails per company compiled to order within 24 hours.

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

Portfolio companies by country

Portfolio companies by city

Other venture fund portfolios

Cite: FundingWatcher, 20 startups, 16 November 2026. https://fundingwatcher.com/startups/investor/novartis-venture-fund/